AVEO Pharmaceuticals Newswire

AVEO Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for AVEO Pharmaceuticals.

Results 1 - 20 of 84 in AVEO Pharmaceuticals

  1. New Market Study, "Fibroblast Growth Factor Receptor 4 - Pipeline...Read the original story w/Photo

    Monday Sep 19 | SBWire

    ... Companies Mentioned in this Report: Amgen Inc., ArQule, Inc., Astellas Pharma Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Blueprint Medicines Corporation, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eddingpharm, Eisai Co., ...

    Comment?

  2. AVEO Pharmaceuticals Inc. (AVEO) Short Interest Up 85.5% in AugustRead the original story w/Photo

    Thursday Sep 15 | AmericanBankingNews.com

    AVEO Pharmaceuticals Inc. was the recipient of a large increase in short interest in August. As of August 31st, there was short interest totalling 1,262,761 shares, an increase of 85.5% from the August 15th total of 680,697 shares.

    Comment?

  3. AVEO Pharmaceuticals Inc. (AVEO) Earns Buy Rating from FBR & CoRead the original story w/Photo

    Tuesday Sep 13 | Daily Political

    ... also recently issued reports on the company. Piper Jaffray Cos. reissued a "buy" rating on shares of AVEO Pharmaceuticals in a research note on Thursday, June 16th. Zacks Investment Research upgraded AVEO Pharmaceuticals from a "hold" rating to a ...

    Comment?

  4. AVEO Pharmaceuticals' (AVEO) Buy Rating Reaffirmed at FBR & CoRead the original story w/Photo

    Tuesday Sep 13 | AmericanBankingNews.com

    ... Tuesday. Several other brokerages have also issued reports on AVEO. Zacks Investment Research upgraded AVEO Pharmaceuticals from a "hold" rating to a "buy" rating and set a $1.00 price target on the stock in a report on Tuesday, May 31st. Piper ...

    Comment?

  5. AVEO Oncology To Present At The 18th Annual Rodman & Renshaw Global Investment ConferenceRead the original story

    Monday Sep 5 | BioSpace

    AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the 18th Annual Rodman & Renshaw Global Investment Conference on Monday, September 12, 2016 at 12:30 PM Eastern Time. The conference is being held at the New York Palace Hotel.

    Comment?

  6. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Tuesday Sep 6 | Business Wire

    Global Professional Luminaires Market 2016-2020 - Key Vendors are Acuity Brands, GE Lighting, OSRAM, Panasonic & Koninklijke Philips - Research and Markets )--Research and Markets has announced the addition of the "Global Professional Luminaires Market 2016-2020" report to their offering.

    Comment?

  7. AVEO Oncology Initiates The Evaluation Of Tivozanib In Combination...Read the original story

    Aug 14, 2016 | BioSpace

    AVEO Oncology today announced the initiation of a clinical evaluation of AVEO's oral, once-daily, vascular endothelial growth factor tyrosine kinase inhibitor , tivozanib, in combination with Bristol-Myers Squibb's anti-PD-1 therapy, OpdivoA , in advanced renal cell carcinoma . Bristol-Myers Squibb will supply nivolumab for use in the Phase 1/2 AVEO-sponsored TiNivo trial.

    Comment?

  8. AVEO Initiates the Evaluation of Tivozanib in Combination with...Read the original story w/Photo

    Aug 15, 2016 | Freshnews

    AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb's Opdivo A in Advanced Renal Cell Carcinoma AVEO Oncology today announced the initiation of a clinical evaluation of AVEO's oral, once-daily, vascular endothelial growth factor tyrosine kinase inhibitor , tivozanib, in combination with Bristol-Myers Squibb's anti-PD-1 therapy, OpdivoA , in advanced renal cell carcinoma . Bristol-Myers Squibb will supply nivolumab for use in the Phase 1/2 AVEO-sponsored TiNivo trial.

    Comment?

  9. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Aug 15, 2016 | Business Wire

    AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb's Opdivo in Advanced Renal Cell Carcinoma )--AVEO Oncology today announced the initiation of a clinical evaluation of AVEO's oral, once-daily, vascular endothelial growth factor tyrosine... )--Mirna Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a pipeline of microRNA-based oncology therapeutics, today reported fina... )--SunLink Corporation and Ganges Internationale Private Limited have entered into a joint venture to accelerate solar deployment in the rapidly growi... )--Clearlake Capital announced that NetMotion Wireless, a provider of mobile security software solutions, has entered into a definitive agreement to be... )--PTC today announced that management will participate in the following conferences.

    Comment?

  10. AVEO Pharmaceuticals Inc. (AVEO) Earns Buy Rating from FBR & CoRead the original story w/Photo

    Aug 12, 2016 | Daily Political

    A number of other research firms have also weighed in on AVEO. Zacks Investment Research lowered shares of AVEO Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, April 15th.

    Comment?

  11. AVEO Pharmaceuticals Inc. (AVEO) Receives "Buy" Rating from FBR & CoRead the original story w/Photo

    Aug 8, 2016 | AmericanBankingNews.com

    's stock had its "buy" rating reaffirmed by research analysts at FBR & Co in a research note issued on Monday. Shares of AVEO Pharmaceuticals traded up 1.01% on Monday, reaching $1.00.

    Comment?

  12. AVEO Oncology Reports Second Quarter 2016 Financial Results And Provides Business UpdateRead the original story

    Aug 3, 2016 | BioSpace

    AVEO Oncology today reported financial results for the second quarter ended June 30, 2016.

    Comment?

  13. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Aug 4, 2016 | Business Wire

    "Our performance this quarter reflects our strong glob... )--Inspyr Therapeutics, Inc. , a clinical-stage biotechnology company developing novel prodrug therapeutics for the treatment of cancer, announces that Chris... )--Trevena, Inc. , a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled r... )--Acceleron Pharma Inc. , a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of highly innovative t... )--hhgregg, Inc. today announced operating results for the first fiscal quarter ended June 30, 2016 as compared to the first fis... )--Five Star Quality Care, Inc. today announced its financial results for the quarter and six months ended June 30, 2016.

    Comment?

  14. FBR & Co Reaffirms "Outperform" Rating for AVEO Pharmaceuticals Inc.Read the original story w/Photo

    Jul 12, 2016 | Daily Political

    ... analysts also recently issued research reports about the company. Zacks Investment Research upgraded AVEO Pharmaceuticals from a hold rating to a buy rating and set a $1.00 price target for the company in a research note on Tuesday, April 26th. ...

    Comment?

  15. AVEO Pharmaceuticals' (AVEO) "Outperform" Rating Reiterated at FBR & CoRead the original story w/Photo

    Jul 9, 2016 | AmericanBankingNews.com

    ... of 216.76% from the company's previous close. An institutional investor recently raised its position in AVEO Pharmaceuticals stock. Renaissance Technologies LLC boosted its position in AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) by 6.0% during the first ...

    Comment?

  16. AVEO Pharmaceuticals Inc. (AVEO) Given Outperform Rating at FBR & CoRead the original story w/Photo

    Jul 7, 2016 | AmericanBankingNews.com

    ... A number of other brokerages have also recently commented on AVEO. Zacks Investment Research upgraded AVEO Pharmaceuticals from a "hold" rating to a "buy" rating and set a $1.00 target price on the stock in a report on Tuesday, April 26th. Piper ...

    Comment?

  17. New Market Research Report: Small-Cell Lung Cancer - Pipeline Review, H1 2016Read the original story w/Photo

    Jun 30, 2016 | PR-inside.com

    ... LLC, AnGes MG, Inc., Antigen Express, Inc., Arbor Vita Corporation, ArQule, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Azaya Therapeutics, Inc., Blirt S.A., Bristol-Myers Squibb Company, Cancer Research Technology Limited, Cellceutix ...

    Comment?

  18. Recent Study: Gallbladder Cancer - Pipeline Review, H1 2016Read the original story w/Photo

    Jun 30, 2016 | SBWire

    ... Inc., Amgen Inc., Arog Pharmaceuticals, Inc., Array BioPharma Inc., Astellas Pharma Inc., AVEO Pharmaceuticals, Inc., Bellicum Pharmaceuticals, Inc., BioLineRx, Ltd., BioSight Ltd., Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers ...

    Comment?

  19. AVEO Pharmaceuticals, Inc. (AVEO) Short Interest Down 30.3% in JuneRead the original story w/Photo

    Jun 28, 2016 | Daily Political

    AVEO Pharmaceuticals, Inc. was the recipient of a significant decline in short interest in June. As of June 15th, there was short interest totalling 456,067 shares, a decline of 30.3% from the May 31st total of 654,025 shares.

    Comment?

  20. AVEO Pharmaceuticals, Inc. (AVEO) Rating Reiterated by FBR & Co.Read the original story w/Photo

    Jun 22, 2016 | Daily Political

    ... issued to clients and investors on Monday. An institutional investor recently raised its position in AVEO Pharmaceuticals stock. Renaissance Technologies LLC increased its stake in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) by 6.0% during the first ...

    Comment?